- Home
- UTL vs RGNX Comparison
UTL vs RGNX Comparison
Compare UTL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | RGNX |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.0M | 761.9M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UTL | RGNX |
|---|---|---|
| Price | $50.84 | $8.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 98.0K | ★ 776.7K |
| Earning Date | 05-05-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | 1.37 | ★ 18.08 |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $536,000,000.00 | $10,393,000.00 |
| Revenue This Year | $7.93 | $50.05 |
| Revenue Next Year | $5.85 | $23.31 |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | 8.33 | ★ 126.48 |
| 52 Week Low | $45.11 | $5.04 |
| 52 Week High | $59.99 | $16.19 |
Technical Indicators
Market Signals| Indicator | UTL | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 38.41 |
| Support Level | $49.13 | $7.83 |
| Resistance Level | $53.19 | $9.28 |
| Average True Range (ATR) | 1.20 | 0.53 |
| MACD | -0.24 | 0.03 |
| Stochastic Oscillator | 9.21 | 3.79 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.